These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. AML1 and AML1 fusion protein AML1-ETO in myeloid gene regulation and leukemogenesis. Zhang DE; Burel S; Zhou L; Hetherington CJ; Yuan Y Blood Cells Mol Dis; 2001; 27(2):368-76. PubMed ID: 11259158 [No Abstract] [Full Text] [Related]
23. AML1-ETO meets JAK2: clinical evidence for the two hit model of leukemogenesis from a myeloproliferative syndrome progressing to acute myeloid leukemia. Schneider F; Bohlander SK; Schneider S; Papadaki C; Kakadyia P; Dufour A; Vempati S; Unterhalt M; Feuring-Buske M; Buske C; Braess J; Wandt H; Hiddemann W; Spiekermann K Leukemia; 2007 Oct; 21(10):2199-201. PubMed ID: 17625612 [No Abstract] [Full Text] [Related]
24. Transient myeloproliferative syndrome/transient acute myeloid leukemia in a newborn with Down syndrome: a case report and literature review. D'Angelo G; Merlo P Lab Hematol; 2003; 9(1):38-41. PubMed ID: 12661826 [TBL] [Abstract][Full Text] [Related]
25. Identification of RUNX1/AML1 as a classical tumor suppressor gene. Silva FP; Morolli B; Storlazzi CT; Anelli L; Wessels H; Bezrookove V; Kluin-Nelemans HC; Giphart-Gassler M Oncogene; 2003 Jan; 22(4):538-47. PubMed ID: 12555067 [TBL] [Abstract][Full Text] [Related]
26. Amplification of AML1 gene is present in childhood acute lymphoblastic leukemia but not in adult, and is not associated with AML1 gene mutation. Penther D; Preudhomme C; Talmant P; Roumier C; Godon A; Méchinaud F; Milpied N; Bataille R; Avet-Loiseau H Leukemia; 2002 Jun; 16(6):1131-4. PubMed ID: 12040444 [TBL] [Abstract][Full Text] [Related]
27. Cryptic chromosomal aberrations leading to an AML1/ETO rearrangement are frequently caused by small insertions. Gamerdinger U; Teigler-Schlegel A; Pils S; Bruch J; Viehmann S; Keller M; Jauch A; Harbott J Genes Chromosomes Cancer; 2003 Mar; 36(3):261-72. PubMed ID: 12557226 [TBL] [Abstract][Full Text] [Related]
29. AML-1 mutations outside the RUNT domain: description of two cases in myeloid malignancies. Carnicer MJ; Nomdedéu JF; Lasa A; Bellido M; Aventín A; Baiget M; Sierra J Leukemia; 2002 Nov; 16(11):2329-32. PubMed ID: 12399980 [No Abstract] [Full Text] [Related]
30. [Loss-of-function of AML1/PEBP2 alpha B and leukemogenesis]. Osato M; Ito Y; Asou N Tanpakushitsu Kakusan Koso; 2000 Jan; 45(1):40-7. PubMed ID: 10643334 [No Abstract] [Full Text] [Related]
31. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder. Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888 [TBL] [Abstract][Full Text] [Related]
32. Oncogenic potential of the RUNX gene family: 'overview'. Ito Y Oncogene; 2004 May; 23(24):4198-208. PubMed ID: 15156173 [TBL] [Abstract][Full Text] [Related]
33. t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy. Yin CC; Cortes J; Barkoh B; Hayes K; Kantarjian H; Jones D Cancer; 2006 Apr; 106(8):1730-8. PubMed ID: 16532439 [TBL] [Abstract][Full Text] [Related]
34. Increased expression of AML1-a and acquired chromosomal abnormalities in childhood acute lymphoblastic leukemia. Gutiérrez-Angulo M; González-García JR; Meza-Espinoza JP; Picos-Cárdenas VJ; Esparza-Flores MA; López-Guido B; Rivera H Hematol Oncol; 2004 Sep; 22(3):85-90. PubMed ID: 15991223 [TBL] [Abstract][Full Text] [Related]
35. Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia. Ter Elst A; Ma B; Scherpen FJ; de Jonge HJ; Douwes J; Wierenga AT; Schuringa JJ; Kamps WA; de Bont ES Cancer Res; 2011 Apr; 71(7):2761-71. PubMed ID: 21447743 [TBL] [Abstract][Full Text] [Related]
36. Down syndrome and leukemia--an overview of cytogenetic and molecular events. Savaşan S; Taub JW; Ravindranath Y Turk J Pediatr; 1997; 39(4):519-31. PubMed ID: 9433155 [No Abstract] [Full Text] [Related]
37. Transient myeloproliferative disorder in a Down's neonate with rearranged T-cell receptor beta gene and evidence of in vivo maturation demonstrated by dual-colour flow cytometric DNA ploidy analysis. Kwong YL; Cheng G; Tang TS; Robertson EP; Lee CP; Chan LC Leukemia; 1993 Oct; 7(10):1667-71. PubMed ID: 8412331 [TBL] [Abstract][Full Text] [Related]
38. Transient abnormal myelopoiesis of infancy associated with trisomy 21. Homans AC; Verissimo AM; Vlacha V Am J Pediatr Hematol Oncol; 1993 Nov; 15(4):392-9. PubMed ID: 8214361 [TBL] [Abstract][Full Text] [Related]
39. Transient myeloproliferative disorder in a neonate with Down syndrome. Raney RB Clin Pediatr (Phila); 1990 Sep; 29(9):547. PubMed ID: 2146998 [No Abstract] [Full Text] [Related]
40. Increased dosage of Runx1/AML1 acts as a positive modulator of myeloid leukemogenesis in BXH2 mice. Yanagida M; Osato M; Yamashita N; Liqun H; Jacob B; Wu F; Cao X; Nakamura T; Yokomizo T; Takahashi S; Yamamoto M; Shigesada K; Ito Y Oncogene; 2005 Jun; 24(28):4477-85. PubMed ID: 15856017 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]